Timothy R Powell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2342542/publications.pdf Version: 2024-02-01



TIMOTHY P. POWELL

#	Article	IF	CITATIONS
1	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7367-7380.	2.0	13
2	Relationship between CRP and depression: A genetically sensitive study in Sri Lanka. Journal of Affective Disorders, 2022, 297, 112-117.	2.0	3
3	Attenuated transcriptional response to pro-inflammatory cytokines in schizophrenia hiPSC-derived neural progenitor cells. Brain, Behavior, and Immunity, 2022, 105, 82-97.	2.0	7
4	Prolactin, Estradiol and Testosterone Differentially Impact Human Hippocampal Neurogenesis in an In Vitro Model. Neuroscience, 2021, 454, 15-39.	1.1	25
5	Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2). Journal of Medical Virology, 2021, 93, 187-189.	2.5	18
6	Influence of the BDNF Val66Met polymorphism on weight loss after bariatric surgery: a 24-month follow-up. Surgery for Obesity and Related Diseases, 2021, 17, 185-192.	1.0	3
7	Genetic risk for severe COVIDâ€19 correlates with lower inflammatory marker levels in a SARSâ€CoVâ€2â€negative cohort. Clinical and Translational Immunology, 2021, 10, e1292.	1.7	4
8	The Role of Inflammatory Proteins in Anti-Glucocorticoid Therapy for Treatment-Resistant Depression. Journal of Clinical Medicine, 2021, 10, 784.	1.0	5
9	Reconsidering the reasons for heightened inflammation in major depressive disorder. Journal of Affective Disorders, 2021, 282, 434-441.	2.0	10
10	Ditching candidate gene association studies: lessons from psychiatric genetics. Revista Brasileira De Psiquiatria, 2021, 43, 342-344.	0.9	4
11	Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. Molecular Medicine, 2021, 27, 105.	1.9	18
12	Telomere length in patients with obesity submitted to bariatric surgery: A systematic review. European Eating Disorders Review, 2021, 29, 842-853.	2.3	6
13	Lithium treatment and human hippocampal neurogenesis. Translational Psychiatry, 2021, 11, 555.	2.4	13
14	Serum from Older Adults Increases Apoptosis and Molecular Aging Markers in Human Hippocampal Progenitor Cells. , 2021, 12, 2151.		10
15	Telomere length and human hippocampal neurogenesis. Neuropsychopharmacology, 2020, 45, 2239-2247.	2.8	25
16	Longitudinal changes in telomere length in a cohort of obese patients submitted to bariatric surgery: a 2-year follow-up. Surgery for Obesity and Related Diseases, 2020, 16, 1794-1801.	1.0	2
17	Interferon-γ signaling in human iPSC–derived neurons recapitulates neurodevelopmental disorder phenotypes. Science Advances, 2020, 6, eaay9506.	4.7	56
18	The behavioral, cellular and immune mediators of HIV-1 acquisition: New insights from population genetics. Scientific Reports, 2020, 10, 3304.	1.6	8

TIMOTHY R POWELL

#	Article	IF	CITATIONS
19	Polygenic risk for circulating reproductive hormone levels and their influence on hippocampal volume and depression susceptibility. Psychoneuroendocrinology, 2019, 106, 284-292.	1.3	18
20	Associations between childhood maltreatment and inflammatory markers. BJPsych Open, 2019, 5, e3.	0.3	14
21	The Psychiatric Risk Gene NT5C2 Regulates Adenosine Monophosphate-Activated Protein Kinase Signaling and Protein Translation in Human Neural Progenitor Cells. Biological Psychiatry, 2019, 86, 120-130.	0.7	42
22	Inflammatory profiles of severe treatment-resistant depression. Journal of Affective Disorders, 2019, 246, 42-51.	2.0	79
23	The polygenic nature of telomere length and the anti-ageing properties of lithium. Neuropsychopharmacology, 2019, 44, 757-765.	2.8	45
24	Telomere length as a predictor of emotional processing in the brain. Human Brain Mapping, 2019, 40, 1750-1759.	1.9	16
25	Translating Schizophrenia Population Genetics Findings to Neurobiological Mechanisms: The Case of KALRN-9. Biological Psychiatry, 2018, 83, e41-e42.	0.7	1
26	Telomere Length and Bipolar Disorder. Neuropsychopharmacology, 2018, 43, 445-453.	2.8	65
27	Genetic Risk for Psychiatric Disorders and Telomere Length. Frontiers in Genetics, 2018, 9, 468.	1.1	20
28	Growth Factor Proteins and Treatment-Resistant Depression: A Place on the Path to Precision. Frontiers in Psychiatry, 2018, 9, 386.	1.3	19
29	Transcriptomic profiling of human hippocampal progenitor cells treated with antidepressants and its application in drug repositioning. Journal of Psychopharmacology, 2017, 31, 338-345.	2.0	16
30	Assessing the contributions of childhood maltreatment subtypes and depression case-control status on telomere length reveals a specific role of physical neglect. Journal of Affective Disorders, 2017, 213, 16-22.	2.0	45
31	Genetic predisposition to advanced biological ageing increases risk for childhood-onset recurrent major depressive disorder in a large UK sample. Journal of Affective Disorders, 2017, 213, 207-213.	2.0	19
32	The genomeâ€wide expression effects of escitalopram and its relationship to neurogenesis, hippocampal volume, and antidepressant response. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 427-434.	1.1	16
33	Inter-individual variation in genes governing human hippocampal progenitor differentiation in vitro is associated with hippocampal volume in adulthood. Scientific Reports, 2017, 7, 15112.	1.6	15
34	Transcriptomics and the mechanisms of antidepressant efficacy. European Neuropsychopharmacology, 2016, 26, 105-112.	0.3	19
35	The inflammatory cytokines: molecular biomarkers for major depressive disorder?. Biomarkers in Medicine, 2015, 9, 169-180.	0.6	31
36	Putative Transcriptomic Biomarkers in the Inflammatory Cytokine Pathway Differentiate Major Depressive Disorder Patients from Control Subjects and Bipolar Disorder Patients. PLoS ONE, 2014, 9, e91076.	1.1	39

TIMOTHY R POWELL

#	Article	IF	CITATIONS
37	Moodâ€ s tabilizers differentially affect housekeeping gene expression in human cells. International Journal of Methods in Psychiatric Research, 2014, 23, 279-288.	1.1	14
38	Alleleâ€specific expression of the serotonin transporter and its transcription factors following lamotrigine treatment in vitro. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 474-483.	1.1	7
39	Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. European Neuropsychopharmacology, 2013, 23, 1105-1114.	0.3	68
40	DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Translational Psychiatry, 2013, 3, e300-e300.	2.4	71
41	ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. Journal of Psychopharmacology, 2013, 27, 609-615.	2.0	20
42	Depressionâ€Related Behavioral Tests. Current Protocols in Mouse Biology, 2012, 2, 119-127.	1.2	82